title: Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.
abstract: It has been shown that inhibitors of the immune system reside in the spleen and inhibit the endogenous antitumor effects of the immune system. We hypothesized that splenectomy would inhibit the growth of relatively large non-small lung cancer (NSCLC) tumors by modulating the systemic inhibition of the immune system, and in particular Myeloid Derived Suppressor Cells (MDSC). The effect of splenectomy was evaluated in several murine lung cancer models. We found that splenectomy reduces tumor growth and the development of lung metastases, but only in advanced tumors. In immune-deficient NOD-SCID mice the effect of splenectomy on tumor growth and metastatic spread disappeared. Splenectomy significantly reduced the presence of MDSC, and especially monocytic-MDSC in the circulation and inside the tumor. Specific reduction of the CCR2+ subset of monocytic MDSC was demonstrated, and the importance of the CCL2-CCR2 axis was further shown by a marked reduction in CCL2 following splenectomy. These changes were followed by changes in the macrophages contents of the tumors to become more antitumorigenic, and by increased activation of CD8+Cytotoxic T-cells (CTL). By MDSC depletion, and adoptive transfer of MDSCs, we demonstrated that the effect of splenectomy on tumor growth was substantially mediated by MDSC cells. We conclude that the spleen is an important contributor to tumor growth and metastases, and that splenectomy can blunt this effect by depletion of MDSC, changing the amount and characteristics of myeloid cells and enhancing activation of CTL.
authors.affiliation: Laboratory of Lung Cancer Research; Institute of Pulmonary Medicine ; Hadassah-Hebrew University Medical Center ; Jerusalem, Israel.
authors.forename: Liran
authors.initials: L
authors.lastname: Levy
authors.affiliation: Laboratory of Lung Cancer Research; Institute of Pulmonary Medicine ; Hadassah-Hebrew University Medical Center ; Jerusalem, Israel.
authors.forename: Inbal
authors.initials: I
authors.lastname: Mishalian
authors.affiliation: Laboratory of Lung Cancer Research; Institute of Pulmonary Medicine ; Hadassah-Hebrew University Medical Center ; Jerusalem, Israel.
authors.forename: Rachel
authors.initials: R
authors.lastname: Bayuch
authors.affiliation: Laboratory of Lung Cancer Research; Institute of Pulmonary Medicine ; Hadassah-Hebrew University Medical Center ; Jerusalem, Israel.
authors.forename: Lida
authors.initials: L
authors.lastname: Zolotarov
authors.affiliation: Laboratory of Lung Cancer Research; Institute of Pulmonary Medicine ; Hadassah-Hebrew University Medical Center ; Jerusalem, Israel.
authors.forename: Janna
authors.initials: J
authors.lastname: Michaeli
authors.affiliation: Laboratory of Lung Cancer Research; Institute of Pulmonary Medicine ; Hadassah-Hebrew University Medical Center ; Jerusalem, Israel ; Thoracic Oncology Research Laboratory; University of Pennsylvania ; Philadelphia, PA, USA.
authors.forename: Zvi G
authors.initials: ZG
authors.lastname: Fridlender
keywords: MDSC; lung cancer; metastases; splenectomy; tumor immunology